Acting through ETA receptors, ET-1 appears to be central in cancer-induced osteoblastic lesions.[36] In animal models, the selective ETA receptor antagonist Atrasentan significantly reduced the osteoblastic response occurring from a ET-1-secreting tumor. This evidence concerns the gene EDN1 and neoplasm.